| Host: |
E. coli |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Formulation: |
Lyophilised from a 0.22 Mu m filtered solution of 50mM Tris, 150mM NaCl, pH 8.0. |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method: |
< 0.1 EU/Mu g of the protein by LAL method. |
| Immunoreactivity: |
1.Measured by its binding ability in a functional ELISA. Immobilized recombinant human TNFSF9 at 2 Mu g/mL (100 Mu L/well) can bind recombinant human TNFRSF9 with a linear range of 40-100 ng/mL.|2.Measured by its binding ability in a functional ELISA |
| Gene Symbol: |
TNFSF9 |
| Gene ID: |
8744 |
| Uniprot ID: |
TNFL9_HUMAN |
| Immunogen: |
Recombinant Human TNFSF9/4-1BB Ligand Protein is produced by E. coli expression system. The target protein is expressed with sequence (Arg71-Glu254) of human 4-1BB Ligand/TNFSF9 (Accession #NP_003802.1) fused with a 6×His tag at the C-terminus. |
| Immunogen Sequence: |
REGPELSPDDPAGLLDLRQG MFAQLVAQNVLLIDGPLSWY SDPGLAGVSLTGGLSYKEDT KELVVAKAGVYYVFFQLELR RVVAGEGSGSVSLALHLQPL RSAAGAAALALTVDLPPASS EARNSAFGFQGRLLHLSAGQ RLGVHLHTEARARHAWQLTQ GATVLGLFRVTPEIPAGLPS PRSE |
| Tissue Specificity | Expressed in brain, placenta, lung, skeletal muscle and kidney. |
| Function | Cytokine that binds to TNFRSF9. Induces the proliferation of activated peripheral blood T-cells. May have a role in activation-induced cell death (AICD). May play a role in cognate interactions between T-cells and B-cells/macrophages. |
| Protein Name | Tumor Necrosis Factor Ligand Superfamily Member 94-1bb Ligand4-1bbl |
| Database Links | Reactome: R-HSA-5669034 |
| Cellular Localisation | MembraneSingle-Pass Type Ii Membrane Protein |
| Alternative Protein Names | Tumor Necrosis Factor Ligand Superfamily Member 9 protein4-1bb Ligand protein4-1bbl proteinTNFSF9 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
